Metformin/rifampicin combination decreases <i>S</i>. <i>aureus</i> load and persisters in Mice. by Xiao-Qi Lin (9548375)

STAT6-driven immunity decreases <i>N</i>. <i>brasiliensis</i> reproductive output and survival within host. by Annabel A. Ferguson (17616286)

Spatial representation of mean annual soil loss increase/decrease derived with the different modeling centers (rows) and time steps (columns) with the SSP5-8.5. by Fabián Santos (8174028)

“…<p>Spatial representation of mean annual soil loss increase/decrease derived with the different modeling centers (rows) and time steps (columns) with the SSP5-8.5.…”

Functions of <i>GmNN1/FT2a</i> in nitrogen nutrition and nodulation. by Xinxin Li (281237)

Cofactors required for Vpu activities. by Charlotte A. Stoneham (10819125)

Mass Spectrometry Experiment 2 and 3: Comparison of Vpu WT and mutants. by Charlotte A. Stoneham (10819125)

Mass Spectrometry Experiment 1: Comparison of Mito Matrix and Vpu WT and mutants. by Charlotte A. Stoneham (10819125)

The decreased inflammation in the liver of the CD45.2⁺ recipient mice that were adoptively transferred with InCsEVs-BMDMs. by Beibei Zhang (509356)

Supplemental Figure 4. Lamp2a Silencing Decreased and Lamp2a Overexpression Increased Luciferase protein levels in CMA-reporter Expressing H9c2 cells. by Rajeshwary Ghosh (9764078)

Mean red and green fluorescence intensity data from three experiments of cyanobacteria. by Emma T. Brentjens (17295999)

Pair-wise comparison of proximity-ome of Vpu-APEX2 compared to the Mito-APEX2. by Charlotte A. Stoneham (10819125)

List of Included studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

NIH score. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

List of excluded studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The mean and standard deviation of parameters. by Sadaf Sepasgozar Sarkhosh (20436143)

“…Secondary outcomes included performance, fear of movement, and perceived ankle instability, measured using the side-hop test, the Tampa Scale for Kinesiophobia (TSK), and the Cumberland Ankle Instability Tool (CAIT), respectively. Results indicated a significant decrease in ML SI in both groups one month after treatment compared to before and after treatment (P = 0.013 and P<0.001, respectively). …”

Role of Ser77 in ACER3 catalytic site. by Jae Kyo Yi (13570063)

Linearity of ACER3 activity assay. by Jae Kyo Yi (13570063)

Additional behavioral patterns in the 5€, 100€, and 1000€ treatments. by Pablo Brañas-Garza (336425)

The kinetics of ACER3 and mutants. by Jae Kyo Yi (13570063)